US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
pharma · Invasive Extraintestinal Pathogenic Escherichia coli Disease · HIV-1 Infection
Zhejiang Xianju Pharmaceutical
Xian-Janssen Pharmaceutical
Zhejiang Xianju Pharmaceutical drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
西安, CN HQ
146 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 西安, CN
- Employees
- 146
- Programs
- 2
- Drugs
- 5
- Patents
- 0
Zhejiang Xianju Pharmaceutical pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Zhejiang Xianju Pharmaceutical drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Zhejiang Xianju Pharmaceutical in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
rilpivirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
US regulatory status: approved.